5466940-FLY-810761-01.indd

Despite the widespread availability of highly effective vaccines, chronic hepatitis B infection remains a major global health issue, and there are >350 million people chronically infected with the virus. The primary goal of current antiviral therapy is suppression of HBV replication and hepatic inflammation, thereby reducing morbidity and mortality by preventing progression to liver fibrosis, cirrhosis and hepatocellular carcinoma.